Trial Profile
In patients with type 2 diabetes the evaluation of Pioglitazone versus glibenclamide or metformin on markers of inflammation, platelets activation, thrombogenesis and oxidative stress
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Jun 2016
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms PRISCA
- Sponsors Takeda Italia Farmaceutici
- 14 May 2009 New trial record